Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 3, 2025

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight

View original at finance.yahoo.com
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight The dynamics of the hemophilia A market are expected to change mainly due to the increase in prev…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • HEMLIBRA's growth curve (US Q1 2025 year-over-year sales) in the United States was flat, indicating increased competition from newer therapies

    80% confidence

  • The total number of diagnosed prevalent cases of Hemophilia A in the 7MM was around 49,500 in 2024

    80% confidence

  • In the 7MM, the highest diagnosed prevalent cases of Hemophilia A were in the United States, accounting for nearly 14,900 cases in 2024

    80% confidence

  • HEMLIBRA has emerged as a first-line prophylactic therapy for Hemophilia A patients with inhibitors

    80% confidence

  • The market size for hemophilia A was found to be USD 12.2 billion in the leading markets in 2024

    80% confidence

  • Giroctocogene fitelparvovec gene therapy for hemophilia A has demonstrated promising results in late-stage trials, significantly reducing bleeding episodes and outperforming traditional treatments

    80% confidence

  • Immune tolerance induction (ITI) therapy continues to be the gold standard for Hemophilia A patients with inhibitors

    80% confidence

  • The diagnosed prevalence of Hemophilia A is expected to rise from 49K in 2024 to 50K by 2034

    80% confidence

  • Improved diagnostic capabilities and increased disease awareness mainly drive the increase in hemophilia A cases

    80% confidence

  • Hemophilia management is shifting toward extended half-life factor therapies and cutting-edge modalities, including siRNA agents, bispecific antibodies, and gene therapy

    80% confidence

  • The dynamics of the hemophilia A market are expected to change mainly due to the increase in prevalence and the launch of upcoming therapies during the forecast period

    80% confidence

  • The United States accounted for approximately 48% of the total hemophilia A treatment market size in the 7MM in 2024

    80% confidence

  • The hemophilia A market is expected to exhibit growth at a CAGR of 2.9% during the forecast period (2025-2034)

    80% confidence

  • The anticipated launch of emerging therapies are poised to transform the hemophilia A market landscape in the coming years

    80% confidence

Cited in these Via News reports